A practical reference on 胰高血糖素受体: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-07 and is reviewed periodically as new material appears.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
A nerve fascicle is a bundle of nerve fibers belonging to a nerve in the peripheral nervous system. A nerve fascicle is also called a fasciculus. In the central nervous system, the analogous structures are known as nerve tracts.
==== Stratified synthesis ==== In addition to modifying the functionality of the ligands and metals themselves, post-synthetic modification can be used to expand upon the structure of the MOF. Using post-synthetic modification MOFs can be converted from a ordered crystalline material toward a heterogeneous porous material. Using post-synthetic techniques, it is possible for the controlled installation of domains within a MOF crystal which exhibit unique structural and functional characteristics. Core-shell MOFs and other layered MOFs have been prepared where layers have unique functionalization but in most cases are crystallographically compatible from layer to layer.
Alanine Arginine Asparagine Aspartic acid Cysteine Glutamic acid Glutamine Glycine Histidine Methionine Proline Serine Valine Amino acids that are both glucogenic and ketogenic, known as amphibolic (mnemonic "PITTT"):
Sources: en.wikipedia.org
Beginning in 1979 Lagin has drawn and photographed many hundreds of abstract, symbolic, representational, and schematic sand drawings; all drawn by him on smooth beach sand during early morning low tides using small sticks from plants grown in his garden with seeds collected from wild places he earlier photographed. For him inscribing his 'seeing' in the sand, as part of the earth and the world, expresses the fundamental natural presence of symbols in nature and the 'grounded-ness' of symbolic feeling and meaning." Lagin's drawings, both representational and abstract, include elemental symbols, imaginary creatures and "biomorphic and geomorphic life forms and their spiritual metaphysical ecologies", personal life scenes and maps, and symbols and visual metaphors derived from natural history, geography, geology, mathematics, electricity and electronic circuitry, physics, optics, chemistry, and from his imagination. Lagin's first oil and acrylic paintings on canvas were done between 1967 and 1970. He did no paintings between 1970 and 1982 while doing music, and all of his early physical paintings were either given away or lost in the 1982 flood in Marin County, California. In 1992 Lagin started digital (electronic) painting and drawing while resuming oil and acrylic painting and drawing on canvas, and art and sand papers. His paintings and drawings, with various forms of representation and abstraction, are of nearby seascapes, landscapes, 'desertscapes', 'homescapes', and 'creatures'.
Christian P. R. Hackenberger (b. Osnabruck, 1976) is a German chemist. He is a professor of Chemical Biology at the Humboldt University of Berlin and heads the research unit Biomolecule Modification and Delivery at the Leibniz Research Institute for Molecular Pharmacology. He is a co-founder of the Munich-based biotech company Tubulis.
== Non-medical hormonal interventions == In addition to the use of medication to produce tumor-suppressing endocrine alterations, destruction of endocrine organs through surgery or radiation therapy are also possible. Surgical castration, or removal of the testes in males and ovaries in females, have been widely used in the past to treat hormone-responsive prostate cancer and breast cancer respectively. However, these invasive methods have been widely supplanted by the use of GnRH agonists, and other forms of pharmacologic castration. There are still situations in which surgical castration may be beneficial such as in special cases for women with high risk BRCA mutations.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。